Oct. 11 (UPI) -- Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first once-weekly treatment for the disease. Hympavzi, made by Pfizer, is the first antitissue-factor pathway inhibitor to be approved for the blood-clotting disorder, as well as the first hemophilia drug to offer a once-weekly treatment regimen. Now it has been given the nod by the Food and Drug Administration , the agency announced . Advertisement Pfizer's new

Tag-uri: Pfizer